3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
6
Leukemia
2
Myelodysplastic Syndromes
1
Leukemia, Myeloid
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Glioma
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Interventions
Imatinib Mesylate
8
venetoclax
6
Cytarabine
5
ponatinib
4
nilotinib
4
Azacitidine
4
zosuquidar trihydrochloride
2
fludarabine
2
bosutinib
2
RO6839921
2
Decitabine
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
spartalizumab
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
pegfilgrastim
1
lestaurtinib
1
gilteritinib
1
flumatinib
1
enasidenib
1
emvododstat
1
blinatumomab
1
asciminib
1
Whole-Body Irradiation
1
N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
1
Lenalidomide
1
Immunotherapy, Adoptive
1
Idarubicin
1
IMC-EB10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid
×
enasidenib
×
Clear all
NCT02577406
2025-05-18
IDHENTIFY
Celgene
Phase 3
Completed
319 enrolled
29 charts